Year: 2018
Type: editorial
Abstract: Over the past two decades, technological advances in percutaneous coronary intervention (PCI) [such as 2 nd generation drug eluting stents (DES), use of transradial access] and antithrombotic therapy (more potent P2Y 12 agents) have made PCI safer and more effective in treating patients with acute coronary syndrome (ACS). The use of direct and indirect thrombin inhibitors along with glycoprotein IIb/IIIa inhibitors (GPI) during PCI have contributed to improved angiographic and clinical outcomes, but at the cost of increased bleeding complications and its attendant risks of morbidity and death (1).
Source: Journal of Thoracic Disease
Authors: Caroline Ong, Sripal Bangalore
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2781789940